Xcelerate, Inc. to Develop Consumer Healthcare Products
Xcelerate, Inc. to Develop Consumer Healthcare Products
Xcelerate, Inc. to Develop Consumer Healthcare Products Based on Its Current Patent Portfolio
Xcelerate公司將在其現有專利組合的基礎上開發消費者保健產品
MAULDIN, SC / ACCESSWIRE / August 30, 2022 / Xcelerate, Inc. (OTCQB:XCRT) today announced that it had begun an initiative to identify marketing/manufacturing partners to assist in the development of over-the-counter healthcare products based on its existing patent portfolio.
南卡羅來納州莫爾丁，ACCESSWIRE/2022年8月30日/Xcelerate，Inc.(場外交易市場代碼：XCRT)今天宣佈，該公司已開始着手尋找營銷/製造合作伙伴，以協助開發基於其現有專利組合的非處方藥保健產品。
"As previously announced, Xcelerate has recently acquired a portfolio of licensed and patented IP from HS Pharmaceutical, representing the culmination of years of research by world renowned scientists and institutions as well as the investment of millions of dollars in development costs. Recent meetings between our advisors and the staff and scientists at HS Pharmaceuticals have resulted in the decision to pursue the development and marketing of certain of these patented technologies as over-the-counter healthcare products. We believe that we will be able to fast track one or more products that will provide revenue potential for Xcelerate in the near term," said Xcelerate CEO Michael O'Shea.
Xcelerate首席執行官Michael O‘Shea説：“正如之前宣佈的那樣，Xcelerate最近從HS製藥公司收購了一系列獲得許可和專利的知識產權，代表着世界知名科學家和機構多年研究的高潮，以及在開發成本上的數百萬美元投資。我們的顧問與HS製藥公司的員工和科學家最近舉行的會議導致了我們決定將這些專利技術中的某些作為非處方藥保健產品進行開發和營銷。我們相信，我們將能夠快速跟蹤一種或多種產品，這些產品將在短期內為Xcelerate帶來收入潛力，”Xcelerate首席執行官邁克爾·奧謝説。
Additional information about Xcelerate's R&D plans can be viewed at the newly updated under the heading of Technology.
有關Xcelerate研發計劃的更多信息，請訪問最新更新的技術標題下的。
ABOUT XCELERATE INC.
關於Xcelerate公司
In May 2020, Xcelerate commenced implementation of a new business plan that encompasses two separate but related businesses within the medical industry, including (i) owning and licensing the rights to various forms of medical equipment and portfolio of patents, patents pending and technology licenses and (ii) development of virtual health technology to assist patients in developing countries obtain medical care by extending the reach of physicians through the use of that technology. For more information visit or contact us at 854-900-2020 or email info@xcelerate.global.
2020年5月，Xcelerate開始實施一項新的業務計劃，該計劃包括醫療行業內兩項獨立但相關的業務，包括(I)擁有和許可各種形式的醫療設備以及專利、正在申請的專利和技術許可證組合，以及(Ii)開發虛擬醫療技術，通過使用該技術擴大醫生的覆蓋範圍，幫助發展中國家的患者獲得醫療服務。欲瞭解更多信息，請訪問或致電854-900-2020聯繫我們，或發送電子郵件至info@xcelerate.global。
SAFE HARBOR
安全港
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
本新聞稿可能包含經修訂的1934年證券交易法(“交易法”)第21E節所指的前瞻性信息，包括與公司、其董事或高級管理人員在以下方面的意圖、信念或當前預期有關的所有不是歷史事實的陳述：(1)公司的融資計劃；(2)影響公司財務狀況或經營結果的趨勢；(3)公司的增長戰略和經營戰略；以及(4)宣佈和支付股息。“可能”、“將”、“將”、“預期”、“估計”、“預期”、“相信”、“打算”以及類似的表述及其變體旨在識別前瞻性陳述。請投資者注意，任何此類前瞻性陳述都不是對未來業績的保證，涉及風險和不確定性，其中許多風險和不確定性超出了公司的控制能力，實際結果可能與前瞻性陳述中預測的結果大不相同 由以下原因導致 各種因素。
SOURCE: Xcelerate, Inc.
資料來源：Xcelerate公司
譯文內容由第三人軟體翻譯。